- Report
- January 2024
- 169 Pages
Global
From €5185EUR$5,250USD£4,314GBP
€7407EUR$7,500USD£6,163GBP
- Report
- January 2024
- 84 Pages
Global
From €2731EUR$2,765USD£2,272GBP
€3901EUR$3,950USD£3,246GBP
- Report
- January 2024
- 179 Pages
Global
From €5496EUR$5,565USD£4,573GBP
€7852EUR$7,950USD£6,533GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €864EUR$875USD£719GBP
€1235EUR$1,250USD£1,027GBP
- Clinical Trials
- January 2024
- 90 Pages
Global
From €1037EUR$1,050USD£863GBP
€1481EUR$1,500USD£1,233GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €864EUR$875USD£719GBP
€1235EUR$1,250USD£1,027GBP
- Report
- January 2024
- 69 Pages
Global
From €2869EUR$2,905USD£2,387GBP
€4099EUR$4,150USD£3,410GBP
- Report
- January 2024
- 99 Pages
Global
From €5496EUR$5,565USD£4,573GBP
€7852EUR$7,950USD£6,533GBP
- Report
- January 2024
- 49 Pages
Global
From €2869EUR$2,905USD£2,387GBP
€4099EUR$4,150USD£3,410GBP
- Report
- November 2024
- 183 Pages
Global
From €4444EUR$4,500USD£3,698GBP
- Report
- July 2024
- 183 Pages
Global
From €4444EUR$4,500USD£3,698GBP
- Report
- July 2024
- 187 Pages
Global
From €4444EUR$4,500USD£3,698GBP
- Report
- May 2024
- 187 Pages
Global
From €4444EUR$4,500USD£3,698GBP
- Report
- April 2024
- 181 Pages
Global
From €4444EUR$4,500USD£3,698GBP
- Report
- July 2024
- 100 Pages
Global
From €2593EUR$2,625USD£2,157GBP
€3704EUR$3,750USD£3,082GBP
- Report
- July 2024
- 150 Pages
Global
From €2593EUR$2,625USD£2,157GBP
€3704EUR$3,750USD£3,082GBP
- Report
- July 2024
- 100 Pages
Global
From €2593EUR$2,625USD£2,157GBP
€3704EUR$3,750USD£3,082GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €864EUR$875USD£719GBP
€1235EUR$1,250USD£1,027GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €864EUR$875USD£719GBP
€1235EUR$1,250USD£1,027GBP
- Report
- October 2024
- 137 Pages
Global
From €2469EUR$2,500USD£2,054GBP
The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share.
The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market.
Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more